Outlook Therapeutics (NASDAQ: OTLK)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.090 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: AVEO Pharmaceuticals (NASDAQ:AVEO), KalVista Pharmaceuticals (NASDAQ:KALV), Vaxxinity (NASDAQ:VAXX), 4D Molecular Therapeutics (NASDAQ:FDMT) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by HC Wainwright & Co. on Thursday, August 27, 2020. The analyst firm set a price target for 5.00 expecting OTLK to rise to within 12 months (a possible 350.45% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $1.11 last updated Today at July 6, 2022, 2:08 PM UTC.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q3 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.